BioGenCell has started developing a worldwide strategic partner network dedicated to developing and improving patient access to its groundbreaking technology and products.
Sanz Medical Center (Laniado Hospital, Netanya, Israel)
The BioGenCell team has a very close working relationship with the hospital’s expert medical team members including Dr. Mark Niven (Director of the Endocrine and Diabetes Unit), Dr. Galit Sivak (Director of Vascular Surgery) and Dr. Shlomo Bulvic (Head of the Haematology Department).
Sanz Medical Center – Laniado Hospital offers its services to over 250,000 people through its various departments and out-patient clinics, including internal medicine, ophthalmology, pediatrics, surgery, ENT, intensive care, gynecology, dialysis, hematology, gastroenterology, oncology, angiography, and orthopedics. The medical center uses the most modern methods: its instruments, equipment, and expert staff have given the Sanz Medical Center its reputation as one of the leading hospitals in Israel.
Laniado Hospital’s motto: “The hospital will aid every person, and this aid will not be technical assistance alone—it will come from the heart. In this hospital, the staff will work as professionals without forgetting the most important aspects of compassion, warmth, and empathy for the patient.
DG06:The Directorate General Operational for Economy, Employment and Research (DGO6), belonging to the Public Service of Wallonia (SPW), is the legal regional administration in charge of implementing and controlling aids granted to industries, academia and research centers for economic policy, employment and training, and research, including European research Programmes. It is the key advisory body for the Regional government authorities involving research and innovation policy. BioGencell has been granted a grant for over 1 million Euros which, beyond the scientific validation and prestige, allows us to embark upon preclinical trials on three new therapeutic indications in order to help suffering patients worldwide.
WBC– incubator: WBC’s mission is to help set up and develop innovative, competitive and sustainable companies in the field of life sciences and biotechnology in Wallonia. The WBC team helps organize and build science, technology and industrial projects using its own financial resources for implementation. It has a network of experts and partners in the public and private sectors which it makes available to beneficiaries. BioGenCell works in collaboration with WBC and has been granted a number of grants to enable its personalized program to develop in the Wallonia region.
In memory of our dear friend, judge and advocate Mr. Armand Broder who was a great supporter and believer in BioGenCell and did above and beyond the call of duty to bring BioGenCell’s disruptive technology to the millions of ‘No Option’ patients in need of treatment worldwide.
Lexlitis Brussels is a multilingual firm committed to the global practice of law, situated at the south of Brussels. Its lawyers combine a broad experience of the Bar – some of them from more than 20 years – and a professional expertise.
The legal staff also includes several stand-in magistrates, an insolvency practitioner, and several provisional receivers.
BioGenCell has joined forces with Newcastle University Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute together with the Laniado diabetes center in Israel, for research on a new regenerative medicine. Both parties have embarked on a collaborative venture, bringing together different cell therapies that are currently pioneered in both countries towards a simple and persuasive new combination therapeutic of donor-derived pancreatic islets and patient’s own endothelial progenitor cells.
Together, Prof. Shaw, Professor of Regenerative Medicine for Diabetes and Honorary Consultant Physician, Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute and Dr. Niven, Director of Endocrine and Diabetes Unit at Laniado Hospital, Israel, are generating a new concept for potentially transforming islet transplant clinical outcomes and are excited about the results of their first joint research grant. The purpose is to produce a novel donor human islet: recipient enriched endothelial progenitor cell combination therapy which will enable rapid reestablishment of a healthy blood supply for the insulin-producing cells after transplantation into the liver.
Preliminary research results show that bringing together experts in islet transplant innovations from Newcastle University, and BioGenCell’s novel patient specific blood-derived therapeutic stem/progenitor cells has real potential for clinical implementation of an entirely new therapeutic combination, perhaps even in the very near future.